Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 24;18(1):72.
doi: 10.1186/s12916-020-01516-x.

Adolescent polycystic ovary syndrome according to the international evidence-based guideline

Alexia S Peña  1 , Selma F Witchel  2 , Kathleen M Hoeger  3 , Sharon E Oberfield  4 , Maria G Vogiatzi  5 , Marie Misso  6 , Rhonda Garad  6 , Preeti Dabadghao  7 , Helena Teede  6
Affiliations

Adolescent polycystic ovary syndrome according to the international evidence-based guideline

Alexia S Peña et al. BMC Med. .

Abstract

Background: Diagnosing polycystic ovary syndrome (PCOS) during adolescence is challenging because features of normal pubertal development overlap with adult diagnostic criteria. The international evidence-based PCOS Guideline aimed to promote accurate and timely diagnosis, to optimise consistent care, and to improve health outcomes for adolescents and women with PCOS.

Methods: International healthcare professionals, evidence synthesis teams and consumers informed the priorities, reviewed published data and synthesised the recommendations for the Guideline. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied to appraise the evidence quality and the feasibility, acceptability, cost, implementation and strength of the recommendations.

Results: This paper focuses on the specific adolescent PCOS Guideline recommendations. Specific criteria to improve diagnostic accuracy and avoid over diagnosis include: (1) irregular menstrual cycles defined according to years post-menarche; > 90 days for any one cycle (> 1 year post-menarche), cycles< 21 or > 45 days (> 1 to < 3 years post-menarche); cycles < 21 or > 35 days (> 3 years post-menarche) and primary amenorrhea by age 15 or > 3 years post-thelarche. Irregular menstrual cycles (< 1 year post-menarche) represent normal pubertal transition. (2) Hyperandrogenism defined as hirsutism, severe acne and/or biochemical hyperandrogenaemia confirmed using validated high-quality assays. (3) Pelvic ultrasound not recommended for diagnosis of PCOS within 8 years post menarche. (4) Anti-Müllerian hormone levels not recommended for PCOS diagnosis; and (5) exclusion of other disorders that mimic PCOS. For adolescents who have features of PCOS but do not meet diagnostic criteria an 'at risk' label can be considered with appropriate symptomatic treatment and regular re-evaluations. Menstrual cycle re-evaluation can occur over 3 years post menarche and where only menstrual irregularity or hyperandrogenism are present initially, evaluation with ultrasound can occur after 8 years post menarche. Screening for anxiety and depression is required and assessment of eating disorders warrants consideration. Available data endorse the benefits of healthy lifestyle interventions to prevent excess weight gain and should be recommended. For symptom management, the combined oral contraceptive pill and/or metformin may be beneficial.

Conclusions: Extensive international engagement accompanied by rigorous processes honed both diagnostic criteria and treatment recommendations for PCOS during adolescence.

Keywords: Adolescents; Diagnosis; Evidence-based; Girls; Polycystic ovary syndrome; Treatment.

PubMed Disclaimer

Conflict of interest statement

Helena Teede: NHMRC grant funding to the institution to undertake this work (Funding disclosure). Kathy Hoeger: Participation in advisory boards for AbbVie and Bayer pharmaceuticals. The pharmaceutical firms listed did not play a role in these guidelines. Other authors have no competing interests.

References

    1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. - PubMed
    1. Hickey M, Doherty DA, Atkinson H, Sloboda DM, Franks S, Norman RJ, Hart R. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod. 2011;26(6):1469–1477. - PubMed
    1. Christensen SB, Black MH, Smith N, Martinez MM, Jacobsen SJ, Porter AH, Koebnick C. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013;100(2):470–477. - PMC - PubMed
    1. Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibanez L, Pena A, Horikawa R, Gomez-Lobo V, Joel D, et al. The diagnosis of polycystic ovary syndrome during adolescence. Hormone Res Paed. 2015;83:376–389. - PubMed
    1. Ibanez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Hormone Res Paed. 2017;88(6):371–395. - PubMed

Publication types